G.I. Research Institute
Welcome,         Profile    Billing    Logout  
 3 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bressler, Brian
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis

Active, not recruiting
4
672
Europe, Canada, US, RoW
Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C
Alimentiv Inc., Takeda Development Center Americas, Inc.
Colitis, Ulcerative
03/26
03/26
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
NCT02721719: The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis

Active, not recruiting
N/A
50
Canada
University of British Columbia
Ulcerative Colitis
12/23
12/24
IBDDysplasia, NCT04067778: IBD Neoplasia Surveillance Pilot RCT

Completed
N/A
600
Canada
Intervention Group, Control Group
Ottawa Hospital Research Institute, Health Sciences Centre, Winnipeg, Manitoba, Western University, Canada, University of Toronto, Hamilton Health Sciences Corporation, Thunder Bay Regional Health Sciences Centre, Eastern Health, McGill University Health Centre/Research Institute of the McGill University Health Centre, Providence Health & Services, Royal Jubilee Hospital, University of Alberta, MOUNT SINAI HOSPITAL, Nova Scotia Health Authority
Inflammatory Bowel Diseases, Colonic Neoplasms, Dysplasia
09/22
10/22
NCT05809999: IBD Neoplasia Surveillance RCT

Recruiting
N/A
1952
Canada
Standard colonoscopy with targeted biopsies
Ottawa Hospital Research Institute
Colonic Neoplasms, Inflammatory Bowel Diseases, Dysplasia
12/25
02/26
Colman, Mari Chris
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis

Active, not recruiting
4
672
Europe, Canada, US, RoW
Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C
Alimentiv Inc., Takeda Development Center Americas, Inc.
Colitis, Ulcerative
03/26
03/26
Ko, Hin Hin
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
NCT03954327: Combination Antiretroviral Therapy (cART) for PBC

Completed
2
37
Canada
Emtricitabine (FTC)/Tenofovir Disoproxil (TDF), Truvada, Raltegravir, Isentress, Placebo Oral Capsule [CEBOCAP], placebo
University of Alberta, Merck Sharp & Dohme LLC
Primary Biliary Cholangitis
10/22
01/24
PACIFIC, NCT05525520 / 2021-002526-25: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Completed
2
62
Europe, Canada, US, RoW
EP547, Placebo
Escient Pharmaceuticals, Inc, Escient Pharmaceuticals, Inc.
Pruritus
07/24
09/24
RESOLVE, NCT05608681: A Trial to Evaluate EP-104IAR in Adults With Eosinophilic Esophagitis (EoE).

Recruiting
1/2
57
Europe, Canada, RoW
EP-104IAR
Eupraxia Pharmaceuticals Inc.
Eosinophilic Esophagitis
12/25
12/25
CaNAL, NCT03569826: Canadian Network for Autoimmune Liver Disease

Recruiting
N/A
2500
Canada
Observational; no intervention
University Health Network, Toronto
Primary Bilary Cirrhosis (PBC), Autoimmune Hepatitis, Overlap Syndrome
12/28
12/28
Zobel, Joshua
EvolvE, NCT05774184 / 2022-001786-12: A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

Active, not recruiting
2
86
Europe, Canada, US, RoW
barzolvolimab, Matching Placebo
Celldex Therapeutics, Celldex Therapeutics, Inc.
Eosinophilic Esophagitis
03/25
08/25
RESOLVE, NCT05608681: A Trial to Evaluate EP-104IAR in Adults With Eosinophilic Esophagitis (EoE).

Recruiting
1/2
57
Europe, Canada, RoW
EP-104IAR
Eupraxia Pharmaceuticals Inc.
Eosinophilic Esophagitis
12/25
12/25
Yamamoto, Leo
RESOLVE, NCT05608681: A Trial to Evaluate EP-104IAR in Adults With Eosinophilic Esophagitis (EoE).

Recruiting
1/2
57
Europe, Canada, RoW
EP-104IAR
Eupraxia Pharmaceuticals Inc.
Eosinophilic Esophagitis
12/25
12/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bressler, Brian
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis

Active, not recruiting
4
672
Europe, Canada, US, RoW
Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C
Alimentiv Inc., Takeda Development Center Americas, Inc.
Colitis, Ulcerative
03/26
03/26
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
NCT02721719: The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis

Active, not recruiting
N/A
50
Canada
University of British Columbia
Ulcerative Colitis
12/23
12/24
IBDDysplasia, NCT04067778: IBD Neoplasia Surveillance Pilot RCT

Completed
N/A
600
Canada
Intervention Group, Control Group
Ottawa Hospital Research Institute, Health Sciences Centre, Winnipeg, Manitoba, Western University, Canada, University of Toronto, Hamilton Health Sciences Corporation, Thunder Bay Regional Health Sciences Centre, Eastern Health, McGill University Health Centre/Research Institute of the McGill University Health Centre, Providence Health & Services, Royal Jubilee Hospital, University of Alberta, MOUNT SINAI HOSPITAL, Nova Scotia Health Authority
Inflammatory Bowel Diseases, Colonic Neoplasms, Dysplasia
09/22
10/22
NCT05809999: IBD Neoplasia Surveillance RCT

Recruiting
N/A
1952
Canada
Standard colonoscopy with targeted biopsies
Ottawa Hospital Research Institute
Colonic Neoplasms, Inflammatory Bowel Diseases, Dysplasia
12/25
02/26
Colman, Mari Chris
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis

Active, not recruiting
4
672
Europe, Canada, US, RoW
Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C
Alimentiv Inc., Takeda Development Center Americas, Inc.
Colitis, Ulcerative
03/26
03/26
Ko, Hin Hin
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
NCT03954327: Combination Antiretroviral Therapy (cART) for PBC

Completed
2
37
Canada
Emtricitabine (FTC)/Tenofovir Disoproxil (TDF), Truvada, Raltegravir, Isentress, Placebo Oral Capsule [CEBOCAP], placebo
University of Alberta, Merck Sharp & Dohme LLC
Primary Biliary Cholangitis
10/22
01/24
PACIFIC, NCT05525520 / 2021-002526-25: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Completed
2
62
Europe, Canada, US, RoW
EP547, Placebo
Escient Pharmaceuticals, Inc, Escient Pharmaceuticals, Inc.
Pruritus
07/24
09/24
RESOLVE, NCT05608681: A Trial to Evaluate EP-104IAR in Adults With Eosinophilic Esophagitis (EoE).

Recruiting
1/2
57
Europe, Canada, RoW
EP-104IAR
Eupraxia Pharmaceuticals Inc.
Eosinophilic Esophagitis
12/25
12/25
CaNAL, NCT03569826: Canadian Network for Autoimmune Liver Disease

Recruiting
N/A
2500
Canada
Observational; no intervention
University Health Network, Toronto
Primary Bilary Cirrhosis (PBC), Autoimmune Hepatitis, Overlap Syndrome
12/28
12/28
Zobel, Joshua
EvolvE, NCT05774184 / 2022-001786-12: A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

Active, not recruiting
2
86
Europe, Canada, US, RoW
barzolvolimab, Matching Placebo
Celldex Therapeutics, Celldex Therapeutics, Inc.
Eosinophilic Esophagitis
03/25
08/25
RESOLVE, NCT05608681: A Trial to Evaluate EP-104IAR in Adults With Eosinophilic Esophagitis (EoE).

Recruiting
1/2
57
Europe, Canada, RoW
EP-104IAR
Eupraxia Pharmaceuticals Inc.
Eosinophilic Esophagitis
12/25
12/25
Yamamoto, Leo
RESOLVE, NCT05608681: A Trial to Evaluate EP-104IAR in Adults With Eosinophilic Esophagitis (EoE).

Recruiting
1/2
57
Europe, Canada, RoW
EP-104IAR
Eupraxia Pharmaceuticals Inc.
Eosinophilic Esophagitis
12/25
12/25

Download Options